Presentation from Thursday around Gene Therapy by our Global Franchise Lead Lena Winstedt (in Swedish):
https://www.redeye.se/video/event-presentation/895934/hansa-biopharma-head-of-science-lena-winstedt-presenterar-pa-redeye-investor-forum-goteborg-20-april?embed
Hansa Biopharma har en betalt digital IR-aftale med ProInvestor.com
https://www.redeye.se/video/event-presentation/895934/hansa-biopharma-head-of-science-lena-winstedt-presenterar-pa-redeye-investor-forum-goteborg-20-april?embed
Hansa Biopharma har en betalt digital IR-aftale med ProInvestor.com
22/4 2023 08:31 ProInvestorNEWS 5
112226 Opdateret analyse fra SEB.
20230421_HNSA_SEB_Light_at_the_end..
20230421_HNSA_SEB_Light_at_the_end..22/4 2023 08:35 ProInvestorNEWS 5112229 Opdatering fra Erik Penser Bank:20230421_HNSA___EP_Hansa_Biopharma..
20230421_HNSA___EP_Hansa_Biopharma..22/4 2023 08:36 ProInvestorNEWS 5112230 Opdatering fra Carnegie;20230421_HNSA___Carnegie_Sales_sti..
20230421_HNSA___Carnegie_Sales_sti.. Shorting: Active positions for Hansa Biopharma
https://shortnordic.com/detaljer_selskap.php?company=hansa%20biopharma&land=sweden
https://shortnordic.com/detaljer_selskap.php?company=hansa%20biopharma&land=sweden
Urban - I dit link står der: 1.34 %.
If. Finansinspektionen (Blankningsregistret): 4,61% (2023-04-21). Listan uppdaterades: 2023-04-22 00:43)).
If. Finansinspektionen (Blankningsregistret): 4,61% (2023-04-21). Listan uppdaterades: 2023-04-22 00:43)).
24/4 2023 08:47 ProInvestorNEWS 3112281 Hansa Biopharma - Presentation of Q1 interim report 2023
Hansa Biopharma published its Q1 report on April 20th.
On that occasion, HC Andersen Capital will be hosting a digital event on Monday, April 24th at 13.00
https://www.inderes.dk/videos/inderes-presentation-of-q1-2023
Hansa Biopharma published its Q1 report on April 20th.
On that occasion, HC Andersen Capital will be hosting a digital event on Monday, April 24th at 13.00
https://www.inderes.dk/videos/inderes-presentation-of-q1-2023
24/4 2023 13:09 Helge Larsen/PI-redaktør 2112289 The Chicago-based investment bank "William Blair" (analyst Matt Phipps) has initiated coverage on Hansa Biopharma
Hansa Biopharma AB (HNSA) - Turning the TIdeS: Imlifidase Provides a Novel Solution to Widen Transplant Access and Treat Antibody-Driven Acute Disease.
Læs hele analysen:
20230424_HNSA___William_Blair_Turn..
Hansa Biopharma AB (HNSA) - Turning the TIdeS: Imlifidase Provides a Novel Solution to Widen Transplant Access and Treat Antibody-Driven Acute Disease.
Læs hele analysen:
20230424_HNSA___William_Blair_Turn..